Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy
D Ezhilarasan, KS Harini - Oral oncology, 2022 - pubmed.ncbi.nlm.nih.gov
Novel mTOR inhibitors: Promising therapeutic interventions in oral cancer therapy Novel mTOR
inhibitors: Promising therapeutic interventions in oral cancer therapy Oral Oncol. 2022 …
inhibitors: Promising therapeutic interventions in oral cancer therapy Oral Oncol. 2022 …
mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma
SA Nguyen, D Walker, MB Gillespie, JS Gutkind… - … treatment options in …, 2012 - Springer
Opinion statement Head and neck squamous cell carcinomas (HNSCC) represent 6% of all
cancers diagnosed each year in the United States, affecting approximately 43,000 new …
cancers diagnosed each year in the United States, affecting approximately 43,000 new …
Oral toxicity with mTOR inhibitors in cancer therapy
Objectives. The objective of this study was to summarize the cumulative oral toxicities
associated with mTOR inhibitors in published oncology trials with respect to dose, schedule …
associated with mTOR inhibitors in published oncology trials with respect to dose, schedule …
Structural aspects of mTOR inhibitors: search for potential compounds
K Kaur, A Anant, V Asati - Anti-Cancer Agents in Medicinal …, 2022 - ingentaconnect.com
mTOR (mammalian target of rapamycin) is a catalytic subunit composed of two multi-protein
complexes that indicate mTORC1 and mTORC2. It plays a crucial role in various …
complexes that indicate mTORC1 and mTORC2. It plays a crucial role in various …
Targeting the mTOR signaling circuitry in head and neck cancer
P Amornphimoltham, SJ Roth, T Ideker… - Squamous cell …, 2017 - Springer
The recent development of deep-sequencing approaches for the study of human cancer
represents a revolution in medical oncology. These approaches provide an unprecedented …
represents a revolution in medical oncology. These approaches provide an unprecedented …
Therapeutic implication of mTORC2 in oral squamous cell carcinoma
T Naruse, S Yanamoto, K Okuyama, K Yamashita… - Oral Oncology, 2017 - Elsevier
The aim of the present study was to clarify the association of mTORC2 expression with the
cancer progression and the anti-tumor effects of Torin-1 alone and combined treatment with …
cancer progression and the anti-tumor effects of Torin-1 alone and combined treatment with …
Antitumor effect of temsirolimus against oral squamous cell carcinoma associated with bone destruction
T Okui, T Shimo, T Fukazawa, N Kurio… - Molecular cancer …, 2010 - AACR
The mammalian target of rapamycin (mTOR) is engaged in the molecular pathogenesis of
oral squamous cell carcinoma, which frequently invades the maxilla or the mandible …
oral squamous cell carcinoma, which frequently invades the maxilla or the mandible …
mTOR and cancer therapy: clinical development and novel prospects
S Faivre, T Decaens, E Raymond - mTOR Pathway and mTOR Inhibitors in …, 2010 - Springer
Abstract mTOR, a pivotal signal transduction protein involved in multiple cellular functions in
tumors at the level of cancer and stroma cells, represents an attractive target for cancer …
tumors at the level of cancer and stroma cells, represents an attractive target for cancer …
mTOR pathway and mTOR inhibitors in cancer therapy
MS Ernstoff - British Journal of Clinical Pharmacology, 2011 - ncbi.nlm.nih.gov
The latest in the series of monographs Cancer Drug Discovery and Development is mTOR
Pathway and mTOR Inhibitors in Cancer Therapy. Rapamycin was first employed as an …
Pathway and mTOR Inhibitors in Cancer Therapy. Rapamycin was first employed as an …
Pushing the envelope in the mTOR pathway: the second generation of inhibitors
E Vilar, J Perez-Garcia, J Tabernero - Molecular cancer therapeutics, 2011 - AACR
Abstract The phosphatidylinositol-3-kinase (PI3K)/mTOR pathway has been a major focus of
attention for cancer researchers in the past decade. A preliminary and incomplete …
attention for cancer researchers in the past decade. A preliminary and incomplete …